(PDF) Efficacy and Safety of Icotinib as First-Line Therapy

Efficacy and Safety of Icotinib as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer

OncoTargets and Therapy - New Zealand

doi 10.2147/ott.s98363

Full Text

Abstract

Available in full text

Categories

Date

February 1, 2016

Authors

Publisher

Informa UK Limited

Related search

P3.01-94 Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health

Occupational Health

English

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research

Cancer Research

English

Trial-Based Cost-Utility Analysis of Icotinib Versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China

Multidisciplinary

English

OA08 Efficacy and Safety of Sintilimab Combined With 1st Line Chemotherapy in Advanced Squamous Cell Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research

Cancer Research

English

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure

JAMA network open

English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

English